Skip to content
WorldBrand.AI

Shanghai Pharmaceuticals controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2023

    Subsidiary fined and disgorged a total of about RMB 462 million for unfair high-price drug sales

    In 2023, the Shanghai Municipal Administration for Market Regulation found that Shanghai Pharmaceuticals subsidiary Shanghai No. 1 Biochemical & Pharmaceutical Co. abused its dominant market position by selling polymyxin B sulfate for injection at unfairly high prices. It confiscated about RMB 338 million in illegal gains and imposed a fine of about RMB 124 million. The liable party was that subsidiary and the specified drug.

    Source